Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GOIM GRUPPO ONCOLOGICO MERIDIONALE
Femme et Homme Max 99 ans
GOIM GRUPPO ONCOLOGICO MERIDIONALE
MAJ Il y a 4 ans
Bevacizumab+folfiri in untreated patients with advanced colorectal cancer. A phase II multicenter study of the Gruppo Oncologico dell'Italia Meridionale. (GOIM)
Objectively confirmed response rate Time-to- progression
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GOIM GRUPPO ONCOLOGICO MERIDIONALE
MAJ Il y a 4 ans
A MULTICENTER PHASE II STUDY TO EVALUATE ACTIVITY AND TOLERABILITY OF CISPLATIN (CDDP) AND FOTEMUSTINE (FTM) COMBINATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH BRAIN METASTASES
PRIMARY ENDPOINT: Activity and tolerability of Cisplatin and Fotemustine combination with radiotherapy in paztients with advanced NSCLC and brain metastases not amenable to definitive locoregional tre...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GOIM GRUPPO ONCOLOGICO MERIDIONALE
MAJ Il y a 4 ans
multicenter phase II study to evaluate palonosetron +desametasone in the prevention of nausea and vomiting in patientes resected for colon cancer and treated with moderate emetogenus chemotherapy
to evaluate the efficacy of palonosetron + desametasone in the prevention of nausea and vomiting in patients treated with moderate emetogenous chemotherapy
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
GOIM GRUPPO ONCOLOGICO MERIDIONALE
MAJ Il y a 4 ans
Liposomial pegylate doxorubicine and trasuzumab in the first line treatment of the metastatised Her2 positive breast cancer for senior women
To consider the activity of the chemoteraphic combination with the percentage of obiective responses
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
GOIM GRUPPO ONCOLOGICO MERIDIONALE
MAJ Il y a 4 ans
a multicenter phase II trial of nab-paclitaxel and capecitabine as first line treatment in Her-2 neg. metastatic breast cancer studio di fase II, in pazienti affette da carcinoma della mammella metastatico Her-2 neg. e triple neg., I linea, utilizzando ABX e capecitabina
the efficacy of combination in terms of responce rate; the progression free survival valutare l'attivitò di nab-paclitaxel (abraxane) in associazione a capecitabina (xeloda), in termini di rispo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2